RU2316564C2 - Специфические антитела человека для избирательной терапии рака - Google Patents

Специфические антитела человека для избирательной терапии рака Download PDF

Info

Publication number
RU2316564C2
RU2316564C2 RU2003123100/13A RU2003123100A RU2316564C2 RU 2316564 C2 RU2316564 C2 RU 2316564C2 RU 2003123100/13 A RU2003123100/13 A RU 2003123100/13A RU 2003123100 A RU2003123100 A RU 2003123100A RU 2316564 C2 RU2316564 C2 RU 2316564C2
Authority
RU
Russia
Prior art keywords
peptide
molecule
polypeptide according
cells
binding
Prior art date
Application number
RU2003123100/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2003123100A (ru
Inventor
Йошевед ХАГАЙ (IL)
Йошевед ХАГАЙ
Жанет ЛАЗАРОВИЦ (IL)
Жанет ЛАЗАРОВИЦ
Рашель ГИ (IL)
Рашель ГИ
Орли ЛИПШИЦ (IL)
Орли ЛИПШИЦ
Эстер ЗАНТОН (IL)
Эстер ЗАНТОН
Авигдор ЛЕВАНОН (IL)
Авигдор ЛЕВАНОН
Даниэль ПЛАКСИН (IL)
Даниэль ПЛАКСИН
Тувиа ПЕРЕЦ (IL)
Тувиа ПЕРЕЦ
Original Assignee
Сейвиент Фармасьютикэлс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейвиент Фармасьютикэлс, Инк. filed Critical Сейвиент Фармасьютикэлс, Инк.
Publication of RU2003123100A publication Critical patent/RU2003123100A/ru
Application granted granted Critical
Publication of RU2316564C2 publication Critical patent/RU2316564C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2003123100/13A 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака RU2316564C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
RU2003123100A RU2003123100A (ru) 2005-03-10
RU2316564C2 true RU2316564C2 (ru) 2008-02-10

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123100/13A RU2316564C2 (ru) 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005101622A (ru) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) Композиции и способы терапевтического лечения
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2747154C (en) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
WO2016100533A2 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
FI3377103T4 (fi) * 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Моноклональные антитела. /Под ред. Р.Г.КЕННЕТА с соавт. - М.: Медицина, 1983, с.107. *

Also Published As

Publication number Publication date
EP1353937A2 (en) 2003-10-22
KR20030091952A (ko) 2003-12-03
IL156690A0 (en) 2004-01-04
WO2002059264A3 (en) 2003-03-06
EP1353937A4 (en) 2005-04-13
CN1551886A (zh) 2004-12-01
HUP0400775A2 (en) 2007-05-02
PL365758A1 (en) 2005-01-10
MXPA03005944A (es) 2005-04-29
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
BR0116763A (pt) 2004-03-09
NZ527173A (en) 2006-03-31
CA2433227A1 (en) 2002-08-01
RU2003123100A (ru) 2005-03-10
CZ20031983A3 (cs) 2005-07-13
JP2004524023A (ja) 2004-08-12
WO2002059264A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
RU2316564C2 (ru) Специфические антитела человека для избирательной терапии рака
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
RU2317999C2 (ru) SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20240294648A1 (en) MANAbodies AND METHODS OF USING
Kriangkum et al. Bispecific and bifunctional single chain recombinant antibodies
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
IL291545B1 (en) Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
HRP20010551B1 (hr) Humana monoklonalna antitijela za ctla-4
WO2019030240A1 (en) ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
FI3433280T3 (fi) Proteaasin aktivoimia t-solubispesifisiä molekyylejä
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
AR035581A1 (es) Anticuerpos para il-1beta humana
RU2003133973A (ru) Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело
EP3655437A1 (en) Human antibodies binding to ror2
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
JP2005510246A5 (enExample)
WO2002072832A3 (en) Therapeutic binding molecules
CA2441845A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
US12012450B2 (en) Anti-NKG2A antibodies and compositions
WO2018147960A1 (en) Extension sequences for diabodies
MY143963A (en) Therapeutic binding molecules
KR101828794B1 (ko) 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체
DE10021678A1 (de) Antikörperkonstrukte mit variablen Regionen
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
RU2837590C1 (ru) Антитела против axl и композиции

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080101